VLR-doxorubicin liposomes

VLR-doxorubicin liposomes refer to a targeted drug delivery system where doxorubicin is encapsulated within liposomes modified with the VLR (Val-Leu-Arg) peptide. This specific tripeptide sequence is designed to target the vascular endothelial growth factor receptor (VEGFR) or other components of the tumor neovasculature, thereby enhancing the accumulation of the cytotoxic agent within the tumor microenvironment while minimizing systemic toxicity. Doxorubicin itself is an anthracycline antibiotic that works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and apoptosis. The liposomal formulation provides a protective carrier that extends the half-life of the drug and utilizes the enhanced permeability and retention (EPR) effect, while the VLR peptide adds an active targeting component to improve specificity for angiogenic vessels in solid tumors.

Other names

VLR-doxorubicinVLR-modified doxorubicin liposomesVal-Leu-Arg-targeted liposomal doxorubicin